A strategy referred to as “GVAX”, composed of GM-CSF-engineered irradiated autologous tumor cells, has demonstrated an immunostimulatory effect related to GM-CSF in extensive preclinical results [101]. The gene discussed is CSF2; the disease is neoplasm.